Patents by Inventor Vincent T. GRATTAN
Vincent T. GRATTAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115547Abstract: Disclosed herein are novel uses of amisulpride derivatives and pharmaceutical compositions thereof, alone or in combination with other CNS active agents to antagonize dopamine and/or serotonin (e.g., 5-HT2a, 5-HT7) and/or alpha 2 receptors in a subject. Amisulpride derivatives or pharmaceutical compositions thereof disclosed herein may be used, alone or in combination with other CNS active agents, for the treatment of one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a, 5-HT7) and/or a 2 receptors in a subject. Amisulpride derivatives or pharmaceutical compositions thereof disclosed herein may be used alone or in combination with other CNS active agents for the treatment of one or more disorders associated with abnormal levels of dopamine and/or serotonin in the brain.Type: ApplicationFiled: November 21, 2023Publication date: April 11, 2024Inventors: Andrew R. VAINO, Vincent T. GRATTAN, Zachary PRENSKY
-
Patent number: 11713295Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: GrantFiled: June 21, 2021Date of Patent: August 1, 2023Assignee: LB PHARMACEUTICALS INC.Inventors: Andrew R. Vaino, Vincent T. Grattan, Zachary Prensky
-
Patent number: 11377421Abstract: The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing serotonin (e.g., 5-HT2a, 5-HT7) receptor in a subject, either individually or in combination with one or more other CNS active agents. The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of serotonin (e.g., 5-HT2a, 5-HT7) receptor in a subject, either individually or in combination with one or more other CNS active agents. The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of serotonin in the brain, either individually or in combination with one or more other CNS active agents.Type: GrantFiled: September 23, 2019Date of Patent: July 5, 2022Assignee: LB PHARMACEUTICALS INC.Inventors: Andrew R. Vaino, Vincent T. Grattan, Zachary Prensky
-
Publication number: 20220144770Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: ApplicationFiled: June 21, 2021Publication date: May 12, 2022Inventors: Andrew R. VAINO, Vincent T. GRATTAN, Zachary PRENSKY
-
Patent number: 11040943Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: GrantFiled: September 5, 2019Date of Patent: June 22, 2021Assignee: LB Pharmaceuticals Inc.Inventors: Andrew R. Vaino, Vincent T. Grattan, Zachary Prensky
-
Patent number: 10689338Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: GrantFiled: September 5, 2019Date of Patent: June 23, 2020Assignee: LB Pharmaceuticals Inc.Inventors: Andrew R. Vaino, Vincent T. Grattan, Zachary Prensky
-
Publication number: 20200123102Abstract: The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing serotonin (e.g., 5-HT2a, 5-HT7) receptor in a subject, either individually or in combination with one or more other CNS active agents. The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of serotonin (e.g., 5-HT2a, 5-HT7) receptor in a subject, either individually or in combination with one or more other CNS active agents. The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of serotonin in the brain, either individually or in combination with one or more other CNS active agents.Type: ApplicationFiled: September 23, 2019Publication date: April 23, 2020Applicant: LB PHARMACEUTICALS INC.Inventors: Andrew R. VAINO, Vincent T. GRATTAN, Zachary PRENSKY
-
Publication number: 20200079734Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or a2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: ApplicationFiled: April 15, 2019Publication date: March 12, 2020Inventors: Andrew R. Vaino, Vincent T. Grattan, Zachary Prensky
-
Publication number: 20200055818Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: ApplicationFiled: September 5, 2019Publication date: February 20, 2020Inventors: Andrew R. VAINO, Vincent T. GRATTAN, Zachary PRENSKY
-
Publication number: 20200002277Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: ApplicationFiled: September 5, 2019Publication date: January 2, 2020Inventors: Andrew R. VAINO, Vincent T. Grattan, Zachary Prensky
-
Patent number: 10259786Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of dopamine and/or serotonin in the brain.Type: GrantFiled: November 28, 2017Date of Patent: April 16, 2019Assignee: LB PHARMACEUTICALS INC.Inventors: Andrew R. Vaino, Vincent T. Grattan, Zachary Prensky
-
Patent number: 10167256Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: GrantFiled: February 14, 2018Date of Patent: January 1, 2019Assignee: LB PHARMACEUTICALS INC.Inventors: Andrew R. Vaino, Vincent T. Grattan, Zachary Prensky
-
Publication number: 20180170868Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: ApplicationFiled: February 14, 2018Publication date: June 21, 2018Inventors: Andrew R. VAINO, Vincent T. GRATTAN, Zachary PRENSKY
-
Publication number: 20180155282Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: ApplicationFiled: November 28, 2017Publication date: June 7, 2018Inventors: Andrew R. VAINO, Vincent T. GRATTAN, Zachary PRENSKY